CSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares

Stock News

May 13

CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share repurchases approved by shareholders at the company's annual general meeting held on June 25, 2025, and any subsequent general mandates approved at future general meetings.

The company's core product, CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody), is set to have its latest clinical data presented at the upcoming ASCO Annual Meeting. The timely implementation of this share repurchase plan demonstrates the strong confidence of the company's management and board in its research and development achievements, commercialization progress, and long-term business development. It also reflects the company's commitment to enhancing shareholder value and continuously improving its capital return mechanisms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1197183202"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197183202\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197183202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197183202","market":"other","top_or_hot":-1,"title":"CSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share repurchases approved by shareholders at the company's annual general meeting held on June 25, 2025, and any subsequent general mandates approved at future general meetings.</p>\n<p>The company's core product, CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody), is set to have its latest clinical data presented at the upcoming ASCO Annual Meeting. The timely implementation of this share repurchase plan demonstrates the strong confidence of the company's management and board in its research and development achievements, commercialization progress, and long-term business development. It also reflects the company's commitment to enhancing shareholder value and continuously improving its capital return mechanisms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B Announces Plan to Repurchase Up to 136 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share repurchases approved by shareholders at the company's annual general meeting held on June 25, 2025, and any subsequent general mandates approved at future general meetings.</p>\n<p>The company's core product, CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody), is set to have its latest clinical data presented at the upcoming ASCO Annual Meeting. The timely implementation of this share repurchase plan demonstrates the strong confidence of the company's management and board in its research and development achievements, commercialization progress, and long-term business development. It also reflects the company's commitment to enhancing shareholder value and continuously improving its capital return mechanisms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1197183202","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197183202","pubTimestamp":1778666667,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02616":"基石药业-B"},"translate_title":"基石药业-B公告拟回购最多1.36亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CSTONE PHARMA-B (02616) has announced its intention to repurchase up to 136 million shares on the open market from time to time. This plan is authorized under the general mandate for share repurchases approved by shareholders at the company's annual general meeting held on June 25, 2025, and any subsequent general mandates approved at future general meetings.\nThe company's core product, CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody), is set to have its latest clinical data presented at the upcoming ASCO Annual Meeting. The timely implementation of this share repurchase plan demonstrates the strong confidence of the company's management and board in its research and development achievements, commercialization progress, and long-term business development. It also reflects the company's commitment to enhancing shareholder value and continuously improving its capital return mechanisms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}